Five Sensory and Stimulation Electrodes, and the Calmare® Pain Therapy Device Offered
Fairfield, CT – January 26, 2017 – Calmare Therapeutics Incorporated, (OTCQB: CTTC) (CTI), the pain mitigation company, has been approved to list and supply four (4) sensory and stimulation electrodes and the Calmare® Pain Therapy Device on the GSA Advantage!® web portal.
"Gaining access to the coveted GSA Advantage! website is a great accomplishment for the Company," said CTI President & CEO Conrad Mir. "Our team advisors, consultants, and specialists have worked very hard and overcome many challenges to reach this point. This milestone simplifies the sale process within the GSA network of hospitals, clinics, physicians, and mobile healthcare locales across the globe."
For a complete list of Calmare medical devices and peripherals with associated GSA contract numbers, please contact the company at: GSA@calmaretherapeutics.com, with "Attn: Government Sales Division" in the subject line.
About GSA Advantage!®
GSA Advantage! is the online shopping and ordering system that provides access to thousands of contractors and millions of supplies (products) and services. Anyone may browse on GSA Advantage!® to view and compare the variety of products and services offered. Federal government employees can make purchases on GSA Advantage!® using a:
- Government-wide commercial purchase card (GSA SmartPay®);
- GSA Activity Address Code (AAC); or
- Department of Defense Activity Address Code (DoDAAC) - limited to purchases of GSA Global Supply items.
State and local government entities can now use GSA Advantage!® to purchase products and services under both the Cooperative Purchasing Program and the Disaster Recovery Purchasing Program. Payments for state and local government purchases on GSA Advantage!® are limited to credit card payments using a state or local government issued credit card.
About the Company
Calmare Therapeutics Incorporated, the Calmare Pain Mitigation Therapy™ company, researches, develops and commercializes chronic, neuropathic pain and wound affliction devices. Our flagship medical device – the Calmare® Pain Therapy Device – is the world's only non-invasive and non-addictive modality that can successfully treat chronic, neuropathic pain. The Company holds a U.S. Food & Drug Administration 510k clearance designation (K081255) on its flagship device, which grants it the exclusive right to sell, market, research and develop the medical device in the United States. Calmare Devices are commercially sold to medical practices throughout the world. They are also found in U.S. military hospitals, clinics and on installations via CTI’s General Services Administration (GSA) military contract (V797P-4300B).
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.